Health care stocks were flat to higher pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) inactive and the iShares Biotechnology ETF (IBB) up 0.9%.
United Therapeutics (UTHR) shares were up more than 16% after the company said a pivotal study of nebulized Tyvaso in idiopathic pulmonary fibrosis met the primary efficacy endpoint, increasing forced vital capacity by 130.1 mL at 52 weeks and reducing the risk of clinical worsening compared with placebo.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.